Inovio Pharma (INO) Tops Q1 EPS by 3c; Provides Corp. Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants
May 9, 2016 12:44 PM EDTStifel affirms Inovio Pharma (Nasdaq: INO) with a Buy rating and $13 price target after the copany reported Q1 EPS of ($0.11), which was $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $4.75 million.
Analyst Thomas Shrader commented: Inovio... More
